The Economic Impact of Clinical Research in an Italian Public Hospital: The Malignant Pleural Mesothelioma Case Study
Publish Year: 1397
نوع سند: مقاله ژورنالی
زبان: English
View: 35
This Paper With 10 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_HPM-7-8_007
تاریخ نمایه سازی: 18 مرداد 1403
Abstract:
Background The current economic constraints cause hospital management to use the available public resources as rationally as possible. At the same time, there is the necessity to improve current scientific knowledge. This is even more relevant in the case of patients with malignant pleural mesothelioma (MPM), given the severity of the disease, its dismal prognosis, and the cost of chemotherapy drugs. This work aims to evaluate the standard cost of patients with MPM, supporting physicians in their decision-making process in relation to budget constraints, as well as policymakers with respect research policy. Methods The authors conducted a retrospective cost analysis on all the patients with MPM who were first admitted to a reference hospital specialized in MPM care between ۲۰۱۴ and ۲۰۱۵, collecting data on their diagnostic pathways and active treatments, as well as on the related official fees for each procedure. Then, using a multiple regression model, we estimated the overall expected cost of a patient with MPM treated in our hospital, to be born by the Regional Healthcare System based on the chosen clinical pathway. Results According to results, the economic impact of caring for a patient with MPM is mostly related to the selected active treatments, with drug and hospitalization costs as main drivers. Our analysis suggests that the expected reimbursed fee to care for a patient with MPM is equal to € ۱۸ ۲۱۴.۹۹, with chemotherapy and monitoring costs equal to € ۱۲ ۸۶۱.۴۳ and hospitalization cost equal to € ۵۳۵۳.۵۵. This cost decreases to € ۳۲۰.۱۸ in the case of enrollment in an experimental trial of first-line treatment. In the other cases (second-line or third-line trials), the expected cost borne by the healthcare system for treating patients grows exponentially (€ ۴۰,۱۲۴.۱۸ and € ۵۹ ۸۳۹.۹۴, respectively). Conclusion Experimental trials might be a solution to decrease the economic burden for the public healthcare system only in the case of first-line treatments, where the cost of chemotherapy is relevant. Nevertheless, policy-makers have to accept the sharing of this economic burden between society and the pharmaceutical industry to broaden the current scientific knowledge.
Keywords:
Authors
Roberto Ippoliti
Scientific Promotion, General Hospital of Alessandria, Alessandria, Italy
Greta Falavigna
Research Institute on Sustainable Economic Growth, National Research Council of Italy, Moncalieri, Italy
Federica Grosso
Oncology Unit, General Hospital of Alessandria, Alessandria, Italy
Antonio Maconi
Scientific Promotion, General Hospital of Alessandria, Alessandria, Italy
Lorenza Randi
Scientific Promotion, General Hospital of Alessandria, Alessandria, Italy
Gianmauro Numico
Oncology Unit, General Hospital of Alessandria, Alessandria, Italy
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :